Zelda Therapeutics Ltd (ASX:ZLD) will expand its research program with Curtin University testing cannabinoid extracts to potentially treat pancreatic cancer.
New research activities will investigate the effect of a range of Zelda’s formulations with a focus on animals.
Results from these studies are expected to generate highly relevant data for potential future human clinical trials.
Evidence growing that cannabinoid extract can fight cancer
There is a growing body of evidence that whole plant cannabinoid extracts can impede cancer growth.
READ: Zelda Therapeutics well-funded to advance cannabinoid treatments for medical conditions
Harry Karelis, executive chairman, said: “We are very excited to be able to expand the existing collaboration with Professor Marco Falasca’s team at Curtin University.
“The data to be generated by this new program has the potential to open new avenues of treatment for a cancer with very low survival rates.
“We look forward to results being generated over coming months and progressing the body of knowledge in this important field.”
Pancreatic cancer has a very low survival rate
Pancreatic cancer is the twelfth most common cancer globally, with over 330,000 diagnoses in 2012.
Should Zelda yield successful results from this research program, there is a valuable global market Zelda can tap into.
With a very low five-year survival rate, the pancreatic cancer market will greatly benefit from further research and development using novel approaches.